Preclinical safety and pharmacology of Hematide™, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys

Drug and Chemical Toxicology

Volumn 31, Issue 2, 2008, Pages 229-244

  Woodburn, Kathryn W ^a   Schatz, Peter J ^a   Fong, Kei Lai ^b   Wilson, Susan D ^c   Ferrell, Thomas ^d   Spainhour, Charles B ^d   Norton, Daniel ^d  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

^b Pennsylvania Biolab Inc   (United States)

^c Aclairo Pharmaceutical Development Group Inc   (United States)

^d Calvert Laboratories   (United States)

Author keywords

Anemia; Erythropoiesis stimulating agents; Pharmacology; Safety; Toxicology

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; ERYTHROPOIESIS; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; LOW DRUG DOSE; MALE; MONKEY; NONHUMAN; POLYCYTHEMIA; TOXICOKINETICS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ERYTHROPOIESIS; FEMALE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; PEPTIDES; POLYCYTHEMIA; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

RATTUS;

EID: 40549146218     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540701873186     Document Type: Article

References (22)

1. Arkin, C., Adcock, D., Ernst, D., Marlar, R., Parish, G., Szamosi, D., Warunek, D. (2003). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays; approved guideline-fourth edition. NCCLS document H21-A4 (ISBN 1-56238-521-6).
2. Beguin Y. (1999). Erythropoietin and platelet production. Haematologica 84:541-547.
3. Berridge, M. V., Fraser, J. K., Carter, J. M., Lin, F-K. (1988). Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 72:970-977.
4. Calcieti, P., Veronese, F. M. (2003). Pharmacokinetic and biodistribution properties of poly(ethyleneglycol)-protein conjugates. Adv. Drug Del. Rev. 55:1261-1277.
5. Cowgill, L. D., James, K. M., Levy, J. K., Browne, J. K., Miller, A., Lobingier, R. T., Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., Lykos, M. A. (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31:290-299.
6. Fan, Q., Leuther K. L., Holmes, C. P., Fong, K-L., Zhang, J., Velkovska S., Chen M-J., Mortensen, R. B., Leu, K., Green, J. M., Schatz, P. J., Woodburn K. W. (2006). Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent for the treatment of anemia. Exp. Hematol. 34:1303-1311.
7. U.S. Food and Drug Administration. (2001). FDA Toxicology Review of darbepoetin alfa, BLA 99-1492, Amgen, Inc., approved September 17, 2001. Website accessed on Feb 2, 2008, from http://www.fda.gov/cder/biologics/products/ darbamg091701.htm
8. Greaves P. (2000). Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. New York: Elsevier Science, 2000.
9. Greaves P., Faccini, J. M. (1992). Rat Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies. 2nd ed. Amsterdam, The Netherlands: Elsevier.
10. Maeda, N., Kon, K., Tateishi, N. (1989). Rheological properties of erythrocytes in recombinant human erythropoietin-administered normal rat. Br. J. Haematol. 73:105-111.
11. Moore, D. M. (2000a). Hematology of nonhuman primates In: Feldman, B. F., Zinkl, J. G., Jain, N. C., eds. Schalm's Veterinary Hematology. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins, pp. 1133-1144.
12. Moore, D. M. (2000b). Hematology of the rat (Rattus norvegicus). In: Feldman, B. F., Zinkl, J. G., Jain, N. C., eds. Schalm's Veterinary Hematology. eds. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins, pp. 1210-1224.
13. Muntzel, M., Hannedouche, T., Lacour, B., Drueke T. (1992). Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J. Am. Soc. Nephrol. 3:182-187.
14. Nissenson A. R., Goodnough L. T., Dubois, R. W. (2003) Anemia. Not just an innocent bystander? Arch. Intern. Med. 163:1400-1404.
15. Piron, M., Loo, M., Gothot, A., Tassin, F., Fillet, G., Beguin, Y. (2001). Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 97:442-448.
16. R'zik, S., Loo, M., Beguin, Y. (2001). Reticulocyte transferrin receptor (TfR) expression and contribution to soluble Tfr levels. Haematoligica 86:244-251.
17. Stead, R. B., Lambert, J., Wessels, D., Iwashita, J. S., Leuther, K. K., Woodburn, K. W., Schatz, P. J., Okamoto, D. M., Naso, R., Duliege, A. M. (2006). Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830-1834.
18. Tacey, R., Greway, A., Smiell, J., Power, D., Kromminga, A., Daha, M., Casadevall, N., Kelley, M. (2003). The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Meth. 283:317-329.
19. Watson, A. D. J., Canfield, P. J. (2000). Nutritional deficiency anemias. In: Feldman, B. F., Zinkl, J. G., Jain, N. C., eds. Schalm's Veterinary Hematology, 5th ed. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins, pp. 190-195.
20. Weiss, G., Goodnough, L. T. (2005). Anemia of chronic disease. N. Engl. J. Med. 352: 1011-1023.
21. Woodburn, K. W., Fan, Q., Winslow, S., Chen, M-J., Mortensen, R. B., Casadevall, N., Stead, R. B., Schatz, P. J. (2007). Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp. Hematol. 35:1202-1208.
22. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., Dower, W. J. (1996). Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458-464.